Infections and Related Arthritides

Dolores M., 64, who picks up her grandchildren from school three afternoons a week, developed bacteremic knee sepsis while on adalimumab and methotrexate for rheumatoid arthritis. The disagreement is how much of her antibiotic course, and how much flare risk, to tolerate before restarting the drugs that keep her disease controlled.

Aaron K., 52, a weekly hiker, has knee synovitis that's persisted through two full courses of antibiotics for Lyme arthritis, with a negative synovial PCR. The disagreement is whether that negative result actually settles the question the guideline is built to answer.

Grace O., 41, has symmetric joint pain that's persisted five months after a chikungunya infection caught on a family trip abroad. The one randomized trial in this disease found hydroxychloroquine alone to be the losing option — and the disagreement is what that really means for a patient who doesn't quite match who was actually studied.

Devon L., 27, four months into training for his first triathlon, developed the arthritis and rash of disseminated gonococcal infection. The disagreement is whether guideline-standard ceftriaxone needs backup against rising resistance, and what a real co-infection risk means for his antibiotic plan.

Marlene A., 55, has sung in her church choir for over twenty years and now has visible psoriatic skin lesions alongside joint disease that's outgrown methotrexate. The disagreement is which biologic actually fits a patient whose HIV is so well controlled that her infection risk profile looks different than the textbook caution suggests.

Renee F., 34, a kindergarten teacher, still can't manage the fine motor tasks her job requires two months after a parvovirus B19 infection, with rheumatoid arthritis serology negative on repeat testing. The disagreement comes down to a formal score that falls just short of the threshold that would settle it — leaving the real plan hinging on what happens at the next check-in.